Loading...
Market
Will Eli Lilly's Alzheimer's drug be approved in another major market by end of 2025?
2
Eli Lilly•China•National Medical Products Administration•Eisai•Biogen•Leqembi•United States•Japan•United Kingdom•South Korea
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Eli Lilly or regulatory approval notices
Story
Eli Lilly's Donanemab Approved in China for Early Alzheimer's Treatment, Following Eisai and Biogen's January Approval
Dec 18, 2024, 01:56 AM
Eli Lilly's Alzheimer’s treatment, donanemab, has received approval from China's National Medical Products Administration for use in patients with early symptomatic Alzheimer's disease. This approval offers a new option for patients in China following the earlier approval of Eisai and Biogen's Leqembi in January. Donanemab has previously been authorized in the United States, Japan, and the United Kingdom, expanding its availability for those affected by the disease. The approval comes as a joint research team from South Korea and the U.S. has revealed insights into the mechanism by which tau proteins, linked to Alzheimer's, are removed from the brain.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
South Korea • 25%
Other • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Canada • 25%
Australia • 25%
Germany • 25%
Other • 25%
Approved for preventive use • 25%
Approved with restrictions • 25%
Rejected • 25%
No decision • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
